W. Wang

83 Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus

B. Werneburg, J. Merola, R. Furie, 2017, Lupus Science & Medicine.

SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le

B. Werneburg, J. Merola, L. Stevenson, 2017 .

1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE)

V. Werth, J. Merola, L. Stevenson, 2018 .